Latest Operating Expenses News

Baby Bunting reported a 6.7% rise in revenue to $271.4 million for H1 2026, while statutory net profit after tax fell 52.5%. Adjusted earnings paint a steadier picture with a 4.1% increase in pro forma NPAT.

Judo Capital Holdings has delivered a robust 1H26 result, posting a 26% half-on-half profit before tax increase and upgrading its net interest margin guidance for the second half. The bank’s SME lending franchise continues to expand rapidly, supported by strong deposit growth and a solid capital position.

Judo Capital Holdings Limited has reported a robust half-year result, with profit before tax rising 26% over the prior half and 53% year-on-year, driven by strong SME loan book growth and stable net interest margins.

Challenger Limited reported a solid first half of FY26 with a 2% rise in normalised net profit after tax and record annuity sales. The company also announced a $150 million on-market share buy-back, reflecting confidence in its strong capital position.

H&G High Conviction Limited has significantly reduced its half-year loss following asset divestment and is actively exploring strategic alternatives to enhance shareholder value amid looming ASX re-compliance requirements.

Simonds Group Limited has reported a robust 1H FY26 performance with a 14% revenue increase and strategic entry into Western Australia, signalling confidence in sustained growth.

Audinate has reported a 12% increase in revenue for the first half of FY26, driven by strong bookings and a surge in adaptor product sales. The company also launched its cloud-first Iris video production platform, signalling a strategic push into software-driven AV solutions.

Bendigo and Adelaide Bank reported robust half-year results, driven by digital deposit growth and a strategic acquisition of RACQ Bank’s loan and deposit books. The bank also outlined a comprehensive plan to address AML/CTF compliance issues.

AVITA Medical reported a mixed fourth quarter with revenue pressures easing and full-year growth, underpinned by a new $60 million credit facility and advancing clinical trials.

AVITA Medical closed 2025 with steady revenue growth and over 80% gross margin, setting the stage for a confident revenue forecast of up to US$85 million in 2026. The company also secured a new debt facility with improved terms, underpinning its growth ambitions.

AVITA Medical reported steady Q4 losses amid reimbursement challenges but achieved 11% revenue growth for 2025 and secured a $60 million credit facility to fuel future expansion.

AVITA Medical reported an 11% increase in sales revenue for 2025, driven by deeper market penetration and new product launches, while reducing its net loss by 21%. The company secured a $60 million senior secured credit facility but flagged substantial doubt about its ability to continue as a going concern.